Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity and thereby reduce the risk of posttransplant relapse. This phase 1 study investigated the recommended phase 2 dose (RP2D) of venet...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Jacqueline S., Kim, Haesook T., Murdock, H. Moses, Cutler, Corey S., Brock, Jennifer, Gooptu, Mahasweta, Ho, Vincent T., Koreth, John, Nikiforow, Sarah, Romee, Rizwan, Shapiro, Roman, Loschi, Fiona, Ryan, Jeremy, Fell, Geoffrey, Karp, Hannah Q., Lucas, Fabienne, Kim, Annette S., Potter, Danielle, Mashaka, Thelma, Stone, Richard M., DeAngelo, Daniel J., Letai, Anthony, Lindsley, R. Coleman, Soiffer, Robert J., Antin, Joseph H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714724/
https://www.ncbi.nlm.nih.gov/pubmed/34614506
http://dx.doi.org/10.1182/bloodadvances.2021005566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714724/
https://www.ncbi.nlm.nih.gov/pubmed/34614506
http://dx.doi.org/10.1182/bloodadvances.2021005566

Ejemplares similares